Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors.
Brain research bulletin – January 01, 1997
Source: PubMed
Summary
Ibogaine shows promise in treating drug dependence by reducing stimulant effects, evidenced by animal studies where it decreased motor stimulation and self-administration behaviors. In these studies, ibogaine's action appears to involve multiple receptor systems, including dopamine and serotonin. Binding competition studies indicate its affinity for various receptors, while in vitro perfusion models provide insights into its effects on neurotransmitter systems. This multifaceted interaction highlights ibogaine's potential role in modulating dopamine release through serotonergic pathways, suggesting a complex mechanism of action in addiction treatment.
Abstract
Ibogaine is an indole alkaloid that has been of interest in recent years due to its putative efficacy in the treatment of drug dependence. For the most part, animal data have shown attenuation of some of the effects of stimulant drugs, for example, motor stimulation and self-administration. The mechanism of this inhibition of drug-induced behavior seems to suggest the action of the dopamine, serotonin, NMDA, kappa, and/or sigma receptor sites, as indicated by the affinity of ibogaine to receptor selective ligands in binding competition studies. However, affinity for receptors does not in itself indicate their involvement. In vitro perfusion studies have proven a useful model to study the effect of ibogaine on neurotransmitter systems and the functional effects of such interactions. This review summarizes these data and the support of multiple effects of ibogaine, and the potential importance of its action on serotonergic modulation of dopamine release.